AA Amyloidosis

Slide 1 · AA amyloidosis

Inflammation-associated systemic amyloid deposition

Mechanisms · morphology · clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Connect persistent inflammation with hepatic SAA production and AA fibril deposition.

Recognize the major associated diseases and organ distribution.

Explain renal and systemic morphology and its clinical consequences.

Distinguish confirmation of amyloid from identification of its biochemical type.

Slide 3 · Clinical starting point

A patient with long-standing inflammatory arthritis develops increasing urinary protein excretion. Kidney tissue shows extracellular amyloid deposits.

1. Which precursor protein is implicated by this clinical setting?

2. Why must a biopsy still establish amyloid type?

A clinical association guides suspicion; It does not prove AA composition.

Slide 4 · Amyloidosis: A disorder of extracellular deposits

Amyloid comprises insoluble fibrillar aggregates derived from amyloidogenic proteins.

Deposits accumulate in extracellular tissues and can impair organ architecture.

The term “amyloidosis” encompasses chemically distinct disorders with similar morphology.

Identifying a deposit is a different task from identifying its precursor.

Slide 5 · AA: The biochemical identity

Serum amyloid A (SAA)

Proteolytic AA-derived material

Extracellular AA fibrils

Precursor and fibril are not interchangeable terms.

SAA is the circulating hepatic acute-phase precursor; AA names the deposited amyloid fibril protein.

Slide 6 · Systemic rather than localized disease

Systemic AA amyloidosis

SAA originates predominantly in liver cells.

Deposits arise at multiple distant tissue sites.

Renal and other organ dysfunction may coexist.

Localized amyloidosis

Deposits are restricted to a tissue or site.

May have an unrelated amyloid precursor.

The term does not designate AA automatically.

Slide 7 · A shared amyloid architecture

Misfolding or incomplete degradation

Assembly into aggregates

Nonbranching fibrils

Extracellular deposition

This is a generic amyloid sequence, applied here to SAA-derived protein.

Distinct precursor proteins converge on a similar fibrillar configuration.

Slide 8 · Physical structure of amyloid

Amyloid fibrils have a characteristic cross-β-pleated organization.

Electron microscopy shows continuous, nonbranching fibrils approximately 8–10 nm in diameter.

This shared structure underlies Congo red staining and birefringence.

Appearance under routine stains alone cannot determine the chemical type.

Slide 9 · The AA precursor belongs to an acute-phase response

Sustained inflammation

Increased hepatic SAA synthesis

Persistent circulating SAA

Potential AA fibril formation

The clinical disease supplies the inflammatory stimulus.

Increased SAA is required for this pathway but is not sufficient by itself for deposition.

Slide 10 · Classification by deposited protein

Category

Fibril protein

Precursor / setting

AA

AA

SAA; Chronic inflammatory conditions

AL

Immunoglobulin light chain

Monoclonal plasma-cell proliferation

ATTR

Transthyretin

Wild-type or variant transthyretin

Slide 11 · Why “secondary amyloidosis” is an older name

Historical terminology

“Secondary” reflected an associated inflammatory disorder.

It described a clinical context rather than fibril chemistry.

AA terminology

Identifies the deposited amyloid A protein.

Allows direct comparison with AL and ATTR by composition.

Slide 12 · Historical infectious associations

Tuberculosis was once a prominent underlying condition.

Bronchiectasis and chronic osteomyelitis were also important associations.

Their relative contribution declined after effective antibiotic therapy.

The pathogenic connection is persistent inflammation, not infection of amyloid deposits.

Slide 13 · Present-day inflammatory associations

Inflammatory setting

Examples named by Robbins

Inflammatory arthritis

Rheumatoid arthritis; Ankylosing spondylitis

Inflammatory bowel disease

Crohn disease; Ulcerative colitis

Persistent infection

Historically TB, bronchiectasis, osteomyelitis

Inflammation from injection-related lesions

Chronic skin infections after subcutaneous heroin injection

Slide 14 · Rheumatoid arthritis: Principal association

Rheumatoid arthritis is the most frequently associated condition account.

Its chronic inflammatory activity supplies a sustained acute-phase stimulus.

AA deposition is a systemic complication, not primary articular amyloid formation.

Renal abnormalities in such a patient require tissue and amyloid typing.

Slide 15 · Interpreting the rheumatoid arthritis figure

~3%

Textbook-reported occurrence of amyloidosis in rheumatoid arthritis

About one-half of affected patients have clinically significant amyloidosis. These are textbook contextual estimates, not a claim about present-day risk.

Slide 16 · Other connective-tissue inflammation

Ankylosing spondylitis is explicitly named among associated connective-tissue disorders.

The shared factor is prolonged inflammatory signaling and acute-phase protein production.

A specific inflammatory diagnosis does not imply that every patient forms amyloid.

Duration and intensity of inflammation create biologic exposure, not a standalone diagnostic criterion.

Slide 17 · Inflammatory bowel disease

Crohn disease

Recognized AA-associated inflammatory bowel disorder.

Inflammation can persist or recur for extended periods.

Ulcerative colitis

Also included among recognized associations.

AA is not inferred solely from the IBD label.

Slide 18 · Subcutaneous narcotic injection and AA

Repeated subcutaneous injection

Chronic skin infection

Persistent inflammatory cytokines

SAA elevation and AA risk

“skin-popping” to generalized AA via chronic skin infection.

The associated infection is the explanatory driver; Avoid assuming direct drug-to-fibril toxicity.

Slide 19 · Neoplastic settings mentioned with AA

AA amyloidosis can accompany certain solid tumors and lymphoid neoplasms.

Renal cell carcinoma is identified as the most common associated solid tumor.

Hodgkin lymphoma is another association named in the source.

The chronic inflammatory milieu remains central to the AA mechanism.

Slide 20 · Familial Mediterranean fever: A related AA pathway

Pyrin-associated autoinflammation

Excess IL-1 signaling

Increased hepatic SAA

AA fibril deposition

A hereditary inflammatory syndrome can produce the same AA fibril type.

The inherited disorder and the fibril biochemical identity are separate axes of classification.

Slide 21 · Etiologic groups share one downstream precursor

Chronic inflammatory disease

Persistent infection / lesions

Certain neoplasms

Autoinflammatory syndrome

Different causes converge on inflammatory SAA stimulation.

Each box represents an association; It is not a quantitative comparison.

Slide 22 · Cytokine-mediated hepatic stimulation

Inflammatory process

IL-6 and IL-1 signaling

Hepatic SAA synthesis

SAA in circulation

IL-6 and IL-1 are named examples, not a complete cytokine inventory.

Liver cells as the principal SAA synthesis site.

Slide 23 · Inflammation changes hepatic protein production

SAA is an acute-phase reactant made by liver cells.

Its synthesis rises during inflammatory signaling.

Long-standing inflammation maintains SAA at elevated concentrations.

The precursor response is systemic even when the inflammatory lesion is localized.

Slide 24 · Circulating SAA and lipoproteins

Hepatocyte

SAA secretion

Association with HDL in blood

Availability to tissues

Circulating SAA is described as bound to high-density lipoproteins.

A transport association is not itself proof that an individual will develop AA amyloidosis.

Slide 25 · Normal SAA handling: Soluble degradation

SAA substrate

Macrophage-derived enzymes

Soluble degradation products

No obligatory amyloid deposit

Normally, extracellular protein handling prevents accumulation.

This normal catabolic pathway explains why a rise in SAA alone is insufficient.

Slide 26 · Why elevated SAA alone is insufficient

Increased input

Inflammation amplifies SAA production.

Precursor concentrations may remain raised.

Required additional failure

SAA must escape effective degradation.

Amyloidogenic material must become insoluble and aggregate.

Slide 27 · Proposed mechanism: Incomplete proteolysis

SAA excess

Inadequate enzymatic breakdown

Insoluble AA material

Amyloid fibrils

An enzyme defect as a possible explanation, not an established universal mechanism.

Do not equate a proposed individual susceptibility mechanism with a clinically proven test.

Slide 28 · Proposed mechanism: SAA structural variation

Structurally altered SAA

Resistance to macrophage degradation

Persistence of AA-prone material

Extracellular fibrils

A genetically determined SAA abnormality is another hypothesis in the source.

The excerpt does not supply a specific variant or molecular test.

Slide 29 · What the source establishes—and what it proposes

Robbins statement

Epistemic status

Inflammation induces SAA through IL-6/IL-1

Described mechanism

SAA is normally enzymatically degraded

Described normal pathway

High SAA alone cannot explain deposits

Explicit conclusion

A degradation-enzyme defect predisposes

Proposed explanation

SAA structural abnormality resists breakdown

Alternative proposed explanation

Slide 30 · From prolonged inflammation to tissue damage

Chronic inflammatory drive

Persistent SAA plus failed proteolysis

AA fibrillar aggregates

Extracellular deposition

Tissue distortion / loss of function

A mechanistic synthesis from the textbook; Susceptible intermediate steps are not fully resolved.

An arrow shows the explanatory sequence, not a patient-specific deterministic prediction.

Slide 31 · Proteostasis as a general amyloid mechanism

Normal safeguards

Misfolded intracellular proteins undergo proteasomal degradation.

Extracellular proteins can be processed by macrophages.

Amyloid setting

Quality-control pathways fail to prevent aggregation.

Insoluble fibrils accumulate outside cells.

Slide 32 · Cross-β fibrils create a shared phenotype

Amyloidogenic protein

β-sheet-rich assembly

Nonbranching fibrils

Congo red birefringence

Congo red confirms amyloid architecture; It does not establish AA chemistry.

AL, AA and ATTR differ in precursor despite shared staining behavior.

Slide 33 · Extracellular deposits distort organs

Amyloid between cells / near membranes

Increasing interstitial material

Compression of adjacent cells

Pressure atrophy and dysfunction

Progression is mainly mechanical and architectural.

Deposits can injure tissues without eliciting a proportionate local inflammatory response.

Slide 34 · Organs commonly affected in reactive systemic disease

Kidneys

Glomeruli; Vessels

Liver

Space of Disse

Spleen

White or red pulp

Lymph nodes

Systemic deposits

Adrenals

Systemic deposits

Thyroid

Systemic deposits

Slide 35 · Kidney: The major clinicopathologic target

Renal amyloid is among the most consequential patterns of systemic deposition.

Glomeruli are a principal site; Vessels and interstitium may also be involved.

Early deposition changes mesangial matrix and glomerular capillary walls.

Later glomerular obliteration explains protein loss and renal failure.

Slide 36 · Early glomerular amyloid

Earlier burden

More extensive burden

Schematic — not a histologic specimen

The early morphologic changes can be subtle before the vascular tuft is extensively distorted.

Slide 37 · Progressive glomerular capillary narrowing

Earlier burden

More extensive burden

Schematic — not a histologic specimen

Mesangial expansion and capillary-wall involvement progressively interfere with the filtration apparatus.

Slide 38 · Advanced glomerular obliteration

Earlier burden

More extensive burden

Schematic — not a histologic specimen

Broad masses of deposited amyloid may efface the tuft, creating an obsolescent glomerulus.

Slide 39 · Renal vascular deposits and gross appearance

Gross appearances

Kidneys can initially appear normal in size and color.

Advanced vascular narrowing may produce ischemic shrinkage.

Microscopic compartments

Glomerular deposits predominate.

Arterioles, arteries, and peritubular interstitium may also be involved.

Slide 40 · Glomerular injury explains proteinuria

Mesangial / capillary-wall amyloid

Disrupted glomerular structure

Protein leakage into urine

Possible nephrotic syndrome

Proteinuria is a clinical consequence, not evidence of a particular amyloid fibril type.

Severity depends on the functional impact of renal deposition.

Slide 41 · Advanced renal injury and kidney failure

Persistent amyloid accumulation

Obliteration of glomerular lumens

Progressive loss of filtration

Kidney failure and uremia

Kidney failure is a serious systemic amyloidosis outcome.

Kidney failure as a common cause of death in systemic amyloidosis.

Slide 42 · Spleen: Two morphologic deposition patterns

Pattern

Predominant compartment

Classic gross descriptor

Sago spleen

Splenic follicles

Tapioca-like granules

Lardaceous spleen

Sinus walls and red-pulp connective framework

Confluent map-like deposits

Slide 43 · Sago spleen: Follicular distribution

Schematic — compartment emphasis only

The classic tapioca-like granularity reflects localization to splenic follicles.

Slide 44 · Lardaceous spleen: Red-pulp distribution

Schematic — compartment emphasis only

Confluence of deposits around sinuses and connective tissue produces a map-like pattern.

Slide 45 · Liver: Deposition begins in the space of Disse

Amyloid in space of Disse

Sinusoidal and parenchymal encroachment

Hepatocyte pressure atrophy

Potential parenchymal replacement

This is the microscopic evolution described for hepatic amyloid.

Vascular deposits can accompany sinusoidal involvement.

Slide 46 · Extensive hepatic amyloid may preserve function

Liver enlargement can accompany substantial amyloid deposition.

Sinusoidal deposits compress and distort hepatocytes.

Hepatocyte loss can be striking on microscopic examination.

Nevertheless, liver function is often relatively preserved description.

Slide 47 · Systemic distribution is variable

Usually mentioned in reactive AA

Kidneys, liver, spleen.

Lymph nodes, adrenals and thyroid.

Interpretive caution

Patterns overlap with other systemic amyloid types.

Distribution alone cannot type the fibril protein.

Slide 48 · Gross morphology may be silent or waxy

Even widespread amyloid may not be macroscopically conspicuous.

When deposits are extensive, organs may be enlarged and firm.

Tissues may have a gray, waxy appearance.

Histology is needed to recognize and characterize the deposit.

Slide 49 · Routine H&E: Extracellular hyaline material

Conceptual H&E schematic — not a histologic photomicrograph.

Amorphous and eosinophilic extracellular material.

Often adjacent to basement membranes.

Morphology suggests amyloid but is not definitive.

Slide 50 · Congo red in ordinary transmitted light

Conceptual stain schematic — not a microscope image.

Deposits take up pink-to-red Congo red stain.

This supports the presence of amyloid.

Confirm the expected optical property under polarized light.

Slide 51 · Congo red under polarization

Conceptual optical schematic — not observed polarized microscopy.

Characteristic yellow-green / apple-green birefringence.

Depends on the cross-β fibrillar structure.

Shared by AA, AL, ATTR and other amyloid types.

Slide 52 · Electron microscopy: Amyloid fibrils

Original vector schematic — not an electron micrograph.

Thin continuous fibrils lack branching.

Diameter is approximately 8–10 nm in the source.

Ultrastructure supports amyloid, not its biochemical subtype.

Slide 53 · Sampling tissues to demonstrate amyloid

Approach named by Robbins

Diagnostic role / qualification

Kidney biopsy

Common when renal manifestations are present

Rectal or gingival tissue

Possible sites when systemic disease is suspected

Abdominal fat aspirate

Congo red can detect deposits; Sensitivity is low

Slide 54 · A negative fat aspirate does not exclude disease

Congo red examination of abdominal fat as quite specific.

Its sensitivity is low: A negative result does not rule out systemic amyloidosis.

Persistent suspicion warrants clinicopathologic reassessment and appropriate tissue sampling.

A positive Congo red result still requires fibril typing.

Slide 55 · Finding amyloid ≠ identifying AA

Presence of amyloid

Congo red staining and birefringence.

Characteristic fibrils on electron microscopy.

Confirms a fibrillar deposit.

Amyloid type

Specific immunohistochemistry where validated.

Mass spectrometry when available.

Establishes protein composition.

Slide 56 · Immunohistochemistry for amyloid type

Specific immunohistochemical stains can help distinguish AA, AL and TTR amyloid.

The tissue distribution cannot reliably perform this classification.

Stain interpretation is distinct from generic Congo red positivity.

Typing should inform clinicopathologic attribution rather than merely restating the associated disease.

Slide 57 · Mass spectrometry identifies the deposited protein

Tissue deposit proven as amyloid

Biochemical fibril identification

AA vs AL vs ATTR assignment

Etiologic interpretation

Mass spectrometry as a method able to identify all amyloid types.

Availability is described as restricted to some centers in the source.

Slide 58 · AA-oriented diagnostic reasoning

Compatible clinical setting / organ findings

Histologic demonstration of amyloid

Determine biochemical amyloid type

Investigate relevant inflammatory driver

The arrows are a teaching sequence, not a prescriptive clinical guideline.

Do not classify amyloid as AA from rheumatoid arthritis history alone.

Slide 59 · AA, AL and ATTR: Discriminating features

Feature

AA

AL

ATTR

Typical mechanism

Inflammation / SAA

Plasma-cell light chains

Transthyretin aggregation

Precursor

SAA

Ig light chain

TTR

Amyloid detected by Congo red?

Yes

Yes

Yes

Chemical typing needed?

Yes

Yes

Yes

Slide 60 · Common diagnostic pitfalls

Treating Congo red positivity as sufficient evidence for AA amyloidosis.

Assuming renal disease plus rheumatoid arthritis establishes the fibril composition.

Misreading eosinophilic extracellular material as amyloid without confirmatory stain.

Excluding systemic amyloidosis solely because abdominal fat aspiration is negative.

Slide 61 · Clinical manifestations reflect affected organs

Compartment

General systemic amyloid consequences

Renal

Proteinuria → nephrotic syndrome → kidney failure

Hepatic

Hepatomegaly; Often preserved function despite deposition

Systemic

Weakness, weight loss, lightheadedness may precede specific signs

Vascular / gastrointestinal

Fragility-related bleeding; GI manifestations depend on site

Slide 62 · Case application: Analyze the kidney biopsy

A patient with persistent rheumatoid arthritis has progressive proteinuria. Glomeruli contain amorphous extracellular material, confirmed by Congo red with birefringence.

1. What has been demonstrated with confidence?

2. What additional step identifies the cause of the deposits?

Think in two layers: Presence of amyloid; Biochemical identity of amyloid.

Slide 63 · Case answer: What can be concluded?

Supported conclusion

Systemic amyloidosis is plausible.

Tissue staining establishes amyloid deposits.

Renal involvement explains the proteinuria.

Not yet demonstrated

That the fibril protein is AA.

That rheumatoid arthritis alone explains the biopsy.

That other systemic amyloid types have been excluded.

Slide 64 · Therapeutic implication: Control the driver

Treat underlying inflammatory condition

Reduce sustained inflammatory signaling

Reduce SAA stimulus

Limit ongoing precursor availability

This is a mechanistic rationale; No drug regimens or contemporary guidelines are inferred.

Decreasing AA prevalence with more effective treatment of inflammatory disorders.

Slide 65 · Prognosis depends partly on inflammatory control

Reactive systemic amyloidosis has a somewhat better outlook than AL discussion.

Outcome depends in part on the degree of control of the associated disease.

Already established tissue deposits may not promptly resolve when inflammation is controlled.

Resorption after treatment is reported, but described as rare.

Slide 66 · AA amyloidosis: Integrated causal chain

Long-standing inflammation

IL-6 / IL-1 → hepatic SAA

Impaired complete breakdown (proposed)

Extracellular AA amyloid

Renal and systemic injury

Solid clinical association + proposed susceptibility mechanisms should be distinguished.

The central, source-supported biological axis is inflammation → SAA → AA fibrils.

Slide 67 · Five high-yield distinctions

SAA is the circulating precursor; AA is the deposited fibril protein.

The inflammatory condition is an association, not tissue proof of amyloid chemistry.

High SAA production alone is not sufficient for deposition.

Congo red identifies amyloid; Further typing identifies the fibril.

Kidney involvement links extracellular deposition to proteinuria and failure.

Slide 68 · Self-assessment: Apply the framework

A patient with inflammatory bowel disease has renal proteinuria and Congo red-positive extracellular deposits. A second patient has a plasma-cell neoplasm and Congo red-positive deposits.

1. Can the two tissues be distinguished reliably by Congo red alone?

2. Which protein precursors must be considered in each context?

Use precursor chemistry—not the generic staining reaction—to name the amyloid type.

Slide 69 · Self-assessment: worked interpretation

Shared finding

Both patients have histologically demonstrable amyloid.

The Congo red reaction derives from amyloid fibril architecture.

Different candidate precursors

Inflammatory bowel disease: SAA-derived AA is plausible.

Plasma-cell neoplasm: immunoglobulin light-chain AL is plausible.

Typing is required for attribution.